In testimony to the U.S. International Trade Commission, Stephen Ezell explained why the biotech industry is a key driver of the U.S. economy and global life sciences innovation, and he argued that robust intellectual property standards in the Trans-Pacific Partnership will be critical to both. Ezell notes that the U.S. provides 12 years of IP protection for clinical test data, so it is disappointing that the TPP commits U.S. trading partners to provide eight at most.